ESR1 and breast carcinoma: In the context of therapy, loosing of ERα expression in breast cancer cells causes drug resistance to endocrine therapies based on targeting the ERα like SERM (selective estrogen receptor modulators) or SERD (selective estrogen receptor down regulators).